Edition:
United Kingdom

STADA Arzneimittel AG (STAGn.DE)

STAGn.DE on Xetra

81.34EUR
22 Jun 2018
Change (% chg)

€0.24 (+0.30%)
Prev Close
€81.10
Open
€81.30
Day's High
€81.68
Day's Low
€81.16
Volume
28,376
Avg. Vol
53,275
52-wk High
€90.24
52-wk Low
€56.51

Chart for

About

Stada Arzneimittel AG is a Germany-based holding company active in the pharmaceutical sector and healthcare market. The Company develops and markets products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are Generics and Branded Products. The Generics segment comprises low-priced and... (more)

Overall

Beta: 0.86
Market Cap(Mil.): €5,145.75
Shares Outstanding(Mil.): 62.34
Dividend: 0.72
Yield (%): 0.87

Financials

  STAGn.DE Industry Sector
P/E (TTM): 54.57 30.95 32.74
EPS (TTM): 1.51 -- --
ROI: 4.41 14.84 14.38
ROE: 9.34 16.34 16.08

BRIEF-STADA Says On Track To Meet Targets After Q1 Results

* DGAP-NEWS: STADA ARZNEIMITTEL AG: STADA WITH SOLID BUSINESS DEVELOPMENT IN THE FIRST QUARTER OF 2018

03 May 2018

BRIEF-STADA Says Miguel Pagan To Become Head of Production

* SAYS MIGUEL PAGAN TO BECOME EXECUTIVE BOARD MEMBER FOR PRODUCTION AND DEVELOPMENT

16 Apr 2018

BRIEF-Board Of STADA To File Application Related To Change Of Sub-Segment Of Stock Exchange

* DGAP-ADHOC: STADA ARZNEIMITTEL AG: EXECUTIVE BOARD OF STADA ARZNEIMITTEL AG DECIDES TO FILE APPLICATION RELATED TO CHANGE OF SUB-SEGMENT OF THE STOCK EXCHANGE

23 Mar 2018

BRIEF-STADA Arzneimittel: Domination And Profit And Loss Transfer Agreement Takes Effect

* DOMINATION AND PROFIT AND LOSS TRANSFER AGREEMENT BETWEEN STADA ARZNEIMITTEL AG AND NIDDA HEALTHCARE GMBH TAKES EFFECT / BEGINNING OF ACCEPTANCE PERIOD FOR SEVERANCE OFFER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

20 Mar 2018

BRIEF-STADA Says Domination And Profit And Loss Transfer Agreement With Nidda Healthcare GmbH Takes Effect

* STADA SAYS DOMINATION AND PROFIT AND LOSS TRANSFER AGREEMENT BETWEEN STADA ARZNEIMITTEL AG AND NIDDA HEALTHCARE GMBH TAKES EFFECT

20 Mar 2018

Stada cuts dividend to focus on investments

BERLIN, March 8 German pharamceuticals company Stada is cutting its dividend to instead use the money for investments to grow its business and improve its position in the market.

08 Mar 2018

BRIEF-Stada FY Net Income Down By 1 Pct At EUR 85.3 Mln

* GROUP SALES INCREASED IN 2017 FINANCIAL YEAR BY 8% TO EUR2,313.9M

08 Mar 2018

BRIEF-STADA to propose a dividend of 0.11 euros per share

* DGAP-ADHOC: STADA: EXECUTIVE BOARD AND SUPERVISORY BOARD OF STADA ARZNEIMITTEL AG RESOLVE ON A PROPOSAL FOR THE APPROPRIATION OF PROFITS AND PROPOSE A DIVIDEND IN THE AMOUNT OF EUR0.11 PER SHARE Source text for Eikon: Further company coverage:

08 Mar 2018

BRIEF-Stada Says EMA Starts Evaluation Of Resubmitted Pegfilgrastim Application

* DGAP-NEWS: STADA ARZNEIMITTEL AG: EMA STARTED THE EVALUATION OF RESUBMITTED MARKETING AUTHORISATION APPLICATION FOR BIOSIMILAR PEGFILGRASTIM

02 Mar 2018

Stada names new CEO to replace Albrecht

FRANKFURT, Feb 1 Stada on Thursday named Peter Goldschmidt to take over as chief executive from Sept. 1, replacing Claudio Albrecht after less than a year in office.

01 Feb 2018

Earnings vs. Estimates